146019-45-6

Basic information

• Product Name: (4-AMINO-3-FLUORO-PHENYL)-METHANOL
• Synonyms: 4-AMINO-3-FLUOROBENZYL ALCOHOL;(4-AMINO-3-FLUORO-PHENYL)-METHANOL;2-Fluoro-4-(hydroxymethyl)aniline, (4-Amino-3-fluorophenyl)methanol
• CAS NO: 146019-45-6
• Molecular Formula: C₇H₈FNO
• Molecular Weight: 141.14
• Product Categories: pharmacetical
• Mol File: 146019-45-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: (4-AMINO-3-FLUORO-PHENYL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-AMINO-3-FLUORO-PHENYL)-METHANOL(146019-45-6)
• EPA Substance Registry System: (4-AMINO-3-FLUORO-PHENYL)-METHANOL(146019-45-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 146019-45-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(4-AMINO-3-FLUORO-PHENYL)-METHANOL is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with improved properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, (4-AMINO-3-FLUORO-PHENYL)-METHANOL is used as a precursor in the production of various agrochemicals, potentially enhancing the effectiveness of these products.
Used in Materials Science:
(4-AMINO-3-FLUORO-PHENYL)-METHANOL is utilized as a component in the development of new materials, taking advantage of its unique chemical properties to create innovative material solutions.
Used in Organic Electronics:
(4-AMINO-3-FLUORO-PHENYL)-METHANOL is also used in the field of organic electronics, where its properties can be harnessed to improve the performance of electronic devices and components.
Overall, (4-AMINO-3-FLUORO-PHENYL)-METHANOL has diverse and important applications in the field of chemistry and related industries, making it a valuable compound for research and development.

Upstream product

• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 455-87-8 4-amino-3-fluorobenzoic acid 

Relevant articles and documents

Mechanistic Evaluation of Bioorthogonal Decaging with trans-Cyclooctene: The Effect of Fluorine Substituents on Aryl Azide Reactivity and Decaging from the 1,2,3-Triazoline

Bioorthogonal prodrug activation/decaging strategies need to be selective, rapid and release the drug from the masking group upon activation. The rates of the 1,3-dipolar cycloaddition between a trans-cyclooctene (TCO) and a series of fluorine-substituted

Substituted 3-fluorophenyl methanol compound, pharmaceutical composition and application

The invention relates to a substituted 3-fluorophenyl methanol compound, a pharmaceutical composition and application in the field of chemical pharmacy. The invention relates to the substituted 3-fluorophenyl methanol compound. Compared with valganciclovir and ganciclovir, the effectiveness of the compound is obviously strengthened, the safety performance is greatly improved, the selectivity index is obviously improved, and huge application value is achieved. The invention further discloses application of the substituted 3-fluorophenyl methanol compound serving as an antiviral drug, and specially for application in preparing a drug for preventing and treating cytomegaloviruses. The invention further discloses a pharmaceutical composition containing the compound and application in preparing the drug for treating or preventing the cytomegalovirus infection disease by utilizing the substituted 3-fluorophenyl methanol compound or the pharmaceutical composition thereof.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.